CCM2, Monoclonal Antibody

Monoclonal CCM2; Anti-CCM2; Cerebral cavernous malformation 2; C7orf22; MGC4607; Cerebral cavernous malformations 2 protein; MGC4067; Chromosome 7 open reading frame 22; Malcavernin; CCM2; CCM 2; CCM-2

For Research Use Only. Not for use in diagnostic procedures.

Monoclonal

IgG1

2 E4

Mouse

CCM2 antibody was purified by affinity chromatography.

Supplied in PBS buffer, pH 7.3, containing 1% BSA, 50% glycerol and 0.02% sodium azide.

500 ug-1 mg/ml (lot specific)

Store at 4 degree C for short term storage. Aliquot and store at -20 degree C for long term storage. Avoid repeated freeze/thaw cycles.

Small volumes of anti-CCM2 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Mouse monoclonal CCM2 antibody

Protein Modification & Stress Response

Immunofluorescence (IF), Immunohistochemistry (IHC), Western Blot (WB)

IF: 1:100
IHC: 1:150
WB: 1:2000

Western Blot analysis of HEK293T cell lysates (5 ug) transfected with either recombinant CCM2 protein (Right) or empty vector (Left) detected with CCM2 antibody

Immunohistochemical analysis of CCM2 protein in paraffin embedded Human Kidney tissue using CCM2 antibody

42,073 Da

cerebral cavernous malformation 2

cerebral cavernous malformations 2 protein

Cerebral cavernous malformations 2 protein

C7orf22  [Similar Products]

CCM2_HUMAN

This gene encodes a scaffold protein that functions in the stress-activated p38 Mitogen-activated protein kinase (MAPK) signaling cascade. The protein interacts with SMAD specific E3 ubiquitin protein ligase 1 (also known as SMURF1) via a phosphotyrosine binding domain to promote RhoA degradation. The protein is required for normal cytoskeletal structure, cell-cell interactions, and lumen formation in endothelial cells. Mutations in this gene result in cerebral cavernous malformations. Multiple transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Nov 2009]

CCM2: Component of the CCM signaling pathway which is a crucial regulator of heart and vessel formation and integrity. May act through the stabilization of endothelial cell junctions. May function as a scaffold protein for MAP2K3-MAP3K3 signaling. Seems to play a major role in the modulation of MAP3K3- dependent p38 activation induced by hyperosmotic shock. Defects in CCM2 are the cause of cerebral cavernous malformations type 2 (CCM2). Cerebral cavernous malformations (CCMs) are congenital vascular anomalies of the central nervous system that can result in hemorrhagic stroke, seizures, recurrent headaches, and focal neurologic deficits. CCMs have an incidence of 0.1%-0.5% in the general population and are usually present clinically during the 3rd to 5th decades of life. The lesions are characterized by grossly enlarged blood vessels consisting of a single layer of endothelium and without any intervening neural tissue, ranging in diameter from a few millimeters to several centimeters. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Motility/polarity/chemotaxis; Adaptor/scaffold

Chromosomal Location of Human Ortholog: 7p13

Cellular Component: protein complex; cytoplasm

Molecular Function: protein binding

Biological Process: integrin-mediated signaling pathway; intercellular junction assembly and maintenance; pericardium development; venous blood vessel morphogenesis; in utero embryonic development; multicellular organism growth; stress-activated MAPK cascade; vasculogenesis; inner ear development; endothelial cell development

Disease: Cerebral Cavernous Malformations 2

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.